f Recent Advances in the Management of Malignant Melanoma

References

1. VeronesiU. CascinelliN. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma.Arch. Surg.1991126443844110.1001/archsurg.1991.01410280036004 2009058
   [Google Scholar]
2. HannaS. LoS.N. SawR.P.M. Surgical excision margins in primary cutaneous melanoma: A systematic review and meta-analysis.Eur. J. Surg. Oncol.20214771558157410.1016/j.ejso.2021.02.025 33722422
   [Google Scholar]
3. LensM.B. DawesM. GoodacreT. Newton-BishopJ.A. Elective lymph node dissection in patients with melanoma: Systematic review and meta-analysis of randomized controlled trials.Arch. Surg.2002137445846110.1001/archsurg.137.4.458 11926952
   [Google Scholar]
4. MortonD.L. WenD.R. WongJ.H. Technical details of intraoperative lymphatic mapping for early stage melanoma.Arch. Surg.1992127439239910.1001/archsurg.1992.01420040034005 1558490
   [Google Scholar]
5. AmersiF. MortonD.L. The role of sentinel lymph node biopsy in the management of melanoma.Adv. Surg.20074124125610.1016/j.yasu.2007.05.015 17972569
   [Google Scholar]
6. GershenwaldJ.E. BermanR.S. PorterG. MansfieldP.F. LeeJ.E. RossM.I. Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma.Ann. Surg. Oncol.20007322623110.1007/BF02523658 10791854
   [Google Scholar]
7. PidhoreckyI. LeeR.J. ProulxG. Risk factors for nodal recurrence after lymphadenctomy for melanoma.Ann. Surg. Oncol.200252964972
   [Google Scholar]
8. SlingluffC.L.Jr StidhamK.R. RicciW.M. StanleyW.E. SeiglerH.F. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients.Ann. Surg.1994219212013010.1097/00000658‑199402000‑00003 8129482
   [Google Scholar]
9. MortonD.L. ThompsonJ.F. CochranA.J. Final trial report of sentinel-node biopsy versus nodal observation in melanoma.N. Engl. J. Med.2014370759960910.1056/NEJMoa1310460 24521106
   [Google Scholar]
10. RobertC. KaraszewskaB. SchachterJ. Improved overall survival in melanoma with combined dabrafenib and trametinib.N. Engl. J. Med.20153721303910.1056/NEJMoa1412690 25399551
    [Google Scholar]
11. WolchokJD Chiarion-SileniV GonzalezR CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol20213915_suppl(Suppl.): 9506.10.1200/JCO.2021.39.15_suppl.9506
    [Google Scholar]
12. AsciertoP.A. Del VecchioM. MandaláM. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (Checkmate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.Lancet Oncol.202021111465147710.1016/S1470‑2045(20)30494‑0 32961119
    [Google Scholar]
13. LukeJ.J. RutkowskiP. QueiroloP. KEYNOTE-716 investigators KEYNOTE-716 investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomized, double-blind, phase 3 trial.Lancet20223991718172910.1016/S0140‑6736(22)00562‑1 35367007
    [Google Scholar]
14. EggermontA.M.M. BlankC.U. MandalaM. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: Updated results from the EORTC 1325-MG/KEYNOTE-054 Trial.J. Clin. Oncol.202038333925393610.1200/JCO.20.02110 32946353
    [Google Scholar]
15. LongG.V. HauschildA. SantinamiM. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.N. Engl. J. Med.2017377191813182310.1056/NEJMoa1708539 28891408
    [Google Scholar]
16. EggermontA.M.M. Chiarion-SileniV. GrobJ.J. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.N. Engl. J. Med.2016375191845185510.1056/NEJMoa1611299 27717298
    [Google Scholar]
17. TawbiH.A. SchadendorfD. LipsonE.J. RELATIVITY-047 investigators RELATIVITY-047 investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N. Engl. J. Med.20223861243410.1056/NEJMoa2109970 34986285
    [Google Scholar]
18. KrishnanT. MenziesA.M. Roberts-ThomsonR. Recent advancements in melanoma management.Intern. Med. J.202151332733310.1111/imj.15228 33738950
    [Google Scholar]